The study on cyproterone acetate (Androcur and generics) is available - Ameli.fr
The demonstration of the links between taking cyproterone acetate (Androcur and generics) and the presence of meningioma has been subject to a publication by the National Health Insurance Fund (CNAM), with clinical experts and the National Agency for the Safety of Medicines and Health Products (ANSM).
This study has established that cyproterone acetate promotes the development of meningiom. The prolonged use of cyproterone acetate beyond 6 months, at an average dose, greater than or equal to 25 mg/d, multiplies the risk of meningioma by 7, and by 20 beyond a cumulative dose of 60 g, or 50 mg/d for 5 years, or 25 mg/d for 10 years.
Les prescripteurs d’acétate de cyprotérone (Androcur et génériques) et les patients concernés ont reçu à la mi-juin des courriers d’information rappelant les recommandations de prescription et de surveillance de ces traitements.
Cette étude est disponible sur l’espace « Statistiques et publications » du site ameli.
The study on cyproterone acetate (Androcur and generics) is available - Ameli.fr
Find other articles from Amavea here
